
Opinion|Videos|September 16, 2024
BTK Inhibitor-Associated Adverse Events
The discussion explores the evolution of understanding adverse events (AEs) related to Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia treatment and identifies the primary classwide AEs associated with these therapies.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- How has the understanding of adverse events associated with Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia treatment evolved, and what are the primary classwide adverse events?
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Overcoming Barriers to Kidney-Protective Therapy
2
What Pharmacists Should Know About Novo Nordisk–Eli Lilly GLP-1 Ad Suit
3
Overlooked Coronavirus Protein May Drive Cytokine Storm, Cardiac Injury in Severe COVID-19
4
Biosimilars: A Guide for Pharmacists
5






























































































